Harbin Pharmaceutical Group Co

Harbin Pharmaceutical Group Co Tangible Book Value per Share

The Tangible Book Value per Share of Harbin Pharmaceutical Group Co (600664.SS) as of Oct 31, 2026 is 2.24 CNY. In the previous year, Tangible Book Value per Share was 1.93 CNY — a change of 16.42% (higher).

Tangible Book Value per Share

2.24CNY

YoY

16.42%

Last updated:

Tangible Book Value per Share of Harbin Pharmaceutical Group Co is 2025 2.24 CNY. Tangible Book Value per Share of Harbin Pharmaceutical Group Co was 2024 1.93 CNY. It decreases by 16.42% higher compared to the previous year.

The Harbin Pharmaceutical Group Co Tangible Book Value per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Tangible Book Value per Share
Date
Tangible Book Value per Share
Jan 1, 2018
2.11 CNY
Jan 1, 2019
1.96 CNY
Jan 1, 2020
1.17 CNY
Jan 1, 2021
1.30 CNY
Jan 1, 2022
1.51 CNY
Jan 1, 2023
1.67 CNY
Jan 1, 2024
1.93 CNY
Jan 1, 2025
2.24 CNY
The Harbin Pharmaceutical Group Co Tangible Book Value per Share history
YEARTangible Book Value per ShareYoY
2.24CNY+16.42%
1.93CNY+15.34%
1.67CNY+10.70%
1.51CNY+15.95%
1.30CNY+10.93%
1.17CNY-40.05%
1.96CNY-7.28%
2.11CNY-19.06%
2.61CNY-11.48%
2.95CNY+12.15%
2.63CNY-15.01%
3.09CNY+0.40%
3.08CNY+2.13%
3.01CNY-10.12%
3.35CNY+11.16%
3.02CNY+8.22%
2.79CNY+3.56%
2.69CNY+15.26%
2.34CNY+15.97%
2.01CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Harbin Pharmaceutical Group Co Stock analysis

What does Harbin Pharmaceutical Group Co do? Harbin Pharmaceutical Group Co., Ltd. generates revenue by engaging in the research, development, manufacture, wholesale, and retail of pharmaceutical products. The firm focuses on innovative research and development in high-tech fields such as antibiotics, modern Chinese medicine, and biopharmaceuticals. These activities support its main business sectors, which include antibiotics, over-the-counter drugs and health products, traditional and modern Chinese medicine, biomedicine, and pharmaceutical commerce. The company produces a wide range of items, including calcium gluconate oral solution, zinc gluconate oral solution, amoxicillin capsules, Shuanghuanglian oral solution, alprostadil injection, pediatric paracetamol Huangnamin granules, lacidipine tablets, hydrochloric acid for injection Cefotiam, ibuprofen granules, and Xingaizhonggai high calcium tablets. The business is structured around these diverse product lines, serving the needs of the pharmaceutical commerce sector and consumers requiring specific medical treatments. By covering the entire value chain from research and development to retail, the company monetizes its expertise in high-tech fields. The products listed, such as Shuanghuanglian oral solution and amoxicillin capsules, represent the tangible outputs of its manufacturing and wholesale operations, which are central to its financial model. Harbin Pharmaceutical Group Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Harbin Pharmaceutical Group Co stock

Tangible Book Value per Share of Harbin Pharmaceutical Group Co is 2.24 CNY in 2025.

Tangible Book Value per Share of Harbin Pharmaceutical Group Co changed from 1.93 CNY to 2.24 CNY, representing a 16.42% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Tangible Book Value per Share Harbin Pharmaceutical Group Co since 2006 – with annual values, charts, and detailed analysis.

Tangible book value per share excludes intangible assets and goodwill, providing a more conservative measure of per-share net asset value.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Harbin Pharmaceutical Group Co

All Key Metrics — Harbin Pharmaceutical Group Co